News

Press Releases

Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board

April 26, 2022

SAN FRANCISCO, Calif., April 25, 2022 – Ambagon Therapeutics, a biotechnology company unlocking...

Ambagon Therapeutics Launches with $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline

January 6, 2022

Modular platform enables development of molecular glue stabilizers addressing intrinsically...

In The News

Vortex selected to present on advancements in small-molecule MYC inhibitors at the third annual Science2Startup (S2S) Symposium.

This year’s S2S is led and organized by Kevin Bitterman, Ph.D., Partner at Atlas Venture; Jessica Alston, Ph.D., Partner at F-Prime Capital; Matt Cohen, Ph.D., Managing Partner at Osage University Partners; Joshua Resnick, M.D.

BioSpace | January 4, 2023

Top Life Sciences Startups to Watch in 2023

BioCentury | February 1, 2022

Ambagon: creating molecular glues for disordered proteins

Publications & Presentations

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Cancer Cell, November 11, 2019

A MYC inhibitor selectively alters the MYC and MAX cistromes and modulates the epigenomic landscape to regulate target gene expression Science Advances, April 27, 2022